文献速递临床试验与 GCP

针灸治疗慢性荨麻疹的疗效与安全性:随机假针刺对照预试验研究方案

Efficacy and safety of acupuncture for patients with chronic urticaria: study protocol of a randomized, sham-controlled pilot trial.
PubMed 文献 · Trials · 2019-06-04

本研究为在中国开展的随机、假针刺对照、参与者和评价者盲法的预试验,计划纳入60例慢性荨麻疹患者,按1:1随机分为真针灸组和假针灸组,每组治疗10次、为期2周。主要结局为荨麻疹活动度评分(UAS),次要结局包括瘙痒视觉模拟评分(VAS)、皮肤病生活质量指数(DLQI)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、体液免疫指标、血清总IgE及不良事件。该预试验主要目的是评估试验可行性,并为针灸治疗慢性荨麻疹的疗效与安全性提供初步证据。

要点

  • 预试验纳入60例慢性荨麻疹患者,按1:1随机分为真针灸组与假针灸组,每组治疗10次、为期2周。
  • 主要结局为荨麻疹活动度评分(UAS),次要结局包括瘙痒VAS、DLQI、HAMD、HAMA、体液免疫指标、血清总IgE及不良事件。
  • 该预试验主要目的是评估试验可行性,并为未来大规模随机对照试验提供初步证据。

核心结论

  • 该预试验主要目的是评估试验可行性,并确认针灸治疗慢性荨麻疹疗效与安全性的基本信息。
  • 试验结果将有助于阐明针灸治疗是否对慢性荨麻疹患者的症状改善有益。
  • 该研究结果将为针灸治疗慢性荨麻疹的有效性和安全性提供初步证据。

研究设计与样本

  • 本研究为在中国开展的随机、假针刺对照、参与者盲法和评价者盲法的预试验。
  • 计划纳入60例慢性荨麻疹患者,按1:1比例随机分配至真针灸组和假针灸组,每组治疗10次、为期2周。
  • 试验组接受固定穴位处方的针灸治疗,对照组接受假针灸,即非穴位处的微针灸。

主要发现

  • 主要结局为荨麻疹活动度评分(UAS)。
  • 次要结局包括瘙痒强度视觉模拟评分(VAS)、皮肤病生活质量指数(DLQI)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、体液免疫指标、血清总IgE及不良事件。
  • UAS、瘙痒VAS和DLQI在基线及随机化后1、2、3、4周进行评定。
  • HAMD、HAMA、体液免疫指标和血清总IgE在基线及随机化后2周进行评估。
  • 不良事件在随机化后1周和2周进行汇总。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic urticaria (CU) is a refractory skin disease with long duration and a high recurrence rate. Acupuncture has been widely used for the treatment of CU in clinical practice in China. However, until now, there has been no appropriately designed randomized controlled trial (RCT) to provide explicit evidence about the effectiveness of acupuncture for the treatment of CU worldwide. Therefore, we plan to conduct a pilot study to explore its effectiveness and safety and determine the feasibility of studying acupuncture in a future, full-scale, RCT of CU. METHODS/DESIGN: This randomized, sham-controlled, participant-blinded and assessor-blinded pilot trial is underway in China. A total of 60 participants with CU will be randomly assigned to two groups in a 1:1 ratio: one treated with real acupuncture and the other with sham acupuncture, for 10 sessions over 2 weeks. The experimental group will receive acupuncture on a fixed prescription of acupoints, whereas the control group will receive sham acupuncture, namely minimal acupuncture on non-acupuncture points. The primary outcome will be the urticaria activity score (UAS). The secondary outcomes will include a visual analogue scale (VAS) score for itching intensity, the Dermatology Life Quality Index (DLQI), the Hamilton Depression Scale (HAMD), the Hamilton Anxiety Scale (HAMA), the humoral immunity index, serum total IgE, and adverse events. The UAS, VAS for itching and the DLQI will be conducted at baseline and at 1, 2, 3, and 4 weeks after randomization. The HAMD, HAMA, humoral immunity index, and serum total IgE will be assessed at baseline and at 2 weeks after randomization. Adverse events will be summarized at 1 week and 2 weeks after randomization. DISCUSSION: The pilot study mainly aims to investigate trial feasibility, and confirm basic information about its effects and safety. Results of this trial will help clarify whether the acupuncture treatment is beneficial for symptom improvement in patients with CU. The finding of this study will provide preliminary evidence on the effectiveness and safety of acupuncture for CU. TRIAL REGISTRATION: Acupuncture-Moxibustion Clinical Trial Registry, AMCTR-ICR-18000190 . Registered on 19 June 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shi Y, Zheng H, Zhou S, et al. Efficacy and safety of acupuncture for patients with chronic urticaria: study protocol of a randomized, sham-controlled pilot trial. Trials. 2019. PMID: 31164178. doi:10.1186/s13063-019-3433-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。